IDH1 and central nervous system cancer: Somatic heterozygous mutations in IDH1 and IDH2 occur in up to 60% of central conventional chondrosarcoma, 80% of WHO grade II–IV glioma, 20% of intrahepatic cholangiocarcinoma and 10% of acute myeloid leukemias (AML) [1].